Unity Biotechnology Files 8-K on Shareholder Vote
| Field | Detail |
|---|---|
| Company | Unity Biotechnology, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 19, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Unity Bio had a shareholder vote on Sept 18th, details to follow.
AI Summary
Unity Biotechnology, Inc. filed an 8-K on September 19, 2025, reporting on matters submitted to a vote of its security holders on September 18, 2025. The filing does not detail the specific proposals voted upon or their outcomes.
Why It Matters
This filing indicates a shareholder meeting occurred, which could signal significant corporate decisions or changes being made by Unity Biotechnology.
Risk Assessment
Risk Level: low — The filing is a routine procedural report and does not contain information about financial performance or significant operational changes.
Key Players & Entities
- Unity Biotechnology, Inc. (company) — Registrant
- September 18, 2025 (date) — Date of earliest event reported
- September 19, 2025 (date) — Date of report
FAQ
What specific matters were submitted to a vote of Unity Biotechnology's security holders on September 18, 2025?
The filing does not specify the exact proposals voted on during the September 18, 2025 meeting.
What was the outcome of the matters voted upon by Unity Biotechnology's security holders?
The filing does not disclose the results or outcomes of the votes held on September 18, 2025.
When was this 8-K report filed with the SEC?
This 8-K report was filed on September 19, 2025.
What is the principal executive office address for Unity Biotechnology, Inc.?
The address is 124 Washington Street, Suite 101, Foxborough, Massachusetts 02035.
What is Unity Biotechnology's IRS Employer Identification Number?
Unity Biotechnology's IRS Employer Identification Number is 26-4726035.
Filing Stats: 1,444 words · 6 min read · ~5 pages · Grade level 14.8 · Accepted 2025-09-19 16:56:13
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share UNBX * * As reported i
Filing Documents
- d804178d8k.htm (8-K) — 35KB
- 0001193125-25-209210.txt ( ) — 148KB
- unbx-20250918.xsd (EX-101.SCH) — 2KB
- unbx-20250918_lab.xml (EX-101.LAB) — 18KB
- unbx-20250918_pre.xml (EX-101.PRE) — 11KB
- d804178d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the timing and progress of the Company's planned wind down and dissolution, including the timing of the filing of the Certificate of Dissolution. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including that the Company may not realize any meaningful value from any potential sale, license, monetization and/or divestiture of one or more of the Company's assets and technologies and other risks described in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including, but not limited to, those risks and uncertainties included in the section entitled "Risk Factors," in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on April 22, 2025, in the Company's Definitive Proxy Statement relating to the Company's Special Meeting of Stockholders, filed with the SEC on August 11, 2025, and in the Company's other filings with the SEC. All forward-looking statements in this Current Report on Form 8-K are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Cautionary Information Regarding Trading in the Company's Securities The Company c
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. UNITY BIOTECHNOLOGY, INC. Date: September 19, 2025 By: /s/ Craig Jalbert Craig R. Jalbert President